XML 54 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes
18.
Income Taxes

A summary of the Company’s current and deferred tax provision is as follows:

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Current income tax expense:

 

 

 

 

 

 

Federal

 

$

-

 

 

$

-

 

State

 

 

13

 

 

 

17

 

Total current income tax expense

 

 

13

 

 

 

17

 

Deferred income tax expense (benefit):

 

 

 

 

 

 

Federal

 

 

1

 

 

 

1

 

State

 

 

(1

)

 

 

2

 

Total deferred tax expense

 

 

 

 

 

3

 

Total expense from income taxes

 

$

13

 

 

$

20

 

 

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Federal statutory income tax rate

 

 

21.0

%

 

 

21.0

%

State income taxes, net of federal benefits

 

 

(38.9

)%

 

 

9.8

%

Research and development tax credits

 

 

0.0

%

 

 

1.5

%

Interest accretion expense

 

 

(186.9

)%

 

 

8.6

%

Change in valuation allowance

 

 

269.1

%

 

 

(46.1

)%

Mark to market warrant

 

 

(58.5

)%

 

 

2.8

%

Deferred true-up

 

 

0.2

%

 

 

1.7

%

Stock-based compensation

 

 

(8.2

)%

 

 

0.5

%

Impairment

 

 

5.3

%

 

 

 

Other permanent items

 

 

(3.1

)%

 

 

0.2

%

Effective income tax rate

 

 

(0.0

)%

 

 

0.0

%

 

Net deferred tax liabilities as of December 31, 2022 and 2021 consisted of the following:

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

102,723

 

 

$

88,327

 

Research and development tax credit carryforwards

 

 

5,674

 

 

 

7,672

 

Stock-based compensation expense

 

 

14,321

 

 

 

11,748

 

Startup costs

 

 

588

 

 

 

697

 

Intangible assets

 

 

3,905

 

 

 

4,471

 

Deferred revenue

 

 

1,135

 

 

 

1,103

 

Unicap

 

 

6

 

 

 

6

 

Imputed interest on contingent payments

 

 

5,654

 

 

 

4,410

 

Legal fee capitalization and amortization

 

 

1,342

 

 

 

1,550

 

Capitalized research and development

 

 

19,318

 

 

 

 

Other

 

 

3,121

 

 

 

1,535

 

Total deferred tax assets

 

 

157,787

 

 

 

121,519

 

Deferred tax liabilities:

 

 

 

 

 

 

In-process research and development

 

 

(27,271

)

 

 

(29,232

)

Total deferred tax liabilities

 

 

(27,271

)

 

 

(29,232

)

Valuation allowance

 

 

(130,525

)

 

 

(92,297

)

Net deferred tax liabilities

 

$

(9

)

 

$

(10

)

 

A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

 

 

 

Unrecognized
Tax Benefits

 

Balance at December 31, 2020

 

$

1,028

 

Increase related to current year tax provisions

 

 

242

 

Balance at December 31, 2021

 

$

1,270

 

Decrease related to current year tax provisions

 

 

(242

)

Balance at December 31, 2022

 

$

1,028

 

 

As of December 31, 2022 and 2021, the Company had U.S. federal and state net operating loss carryforwards of $102,723 and $88,327, respectively, which may be available to offset future taxable income and begin to expire in 2040. As of December 31, 2022 and 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $5,674 and $7,672, respectively, which may be available to offset future tax liabilities and begin to expire in 2032.

Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. A corporation that experiences an ownership change is subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate subject to additional adjustments, as required. The Company experienced an ownership change on August 15, 2017. The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development credits before utilization.

The realization of deferred tax assets is dependent upon the Company’s ability to generate taxable income in future years. ASC 740-10, Income Taxes, requires a valuation allowance to be applied against deferred tax assets when it is considered “more likely than not” that some or all of the gross deferred tax assets will not be realized. The Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.

At December 31, 2022, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded valuation allowance against its federal and state gross deferred tax assets.

The impact of an uncertain income tax position is recognized at the largest amount that is “more likely than not” to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.

As of December 31, 2022 and 2021, the Company had gross unrecognized tax benefits of $1,028 and $1,270, respectively. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next 12 months. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2017 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.

During 2021, the Company sold $1,356 of its net operating losses and unused R&D tax credits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer Program. The income resulting from the sale of net operating losses and unused R&D tax credits is recorded as a component of other income (expense) on the consolidated statements of operations for the year ended December 31, 2021.